Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKings Arms Yard Regulatory News (KAY)

Share Price Information for Kings Arms Yard (KAY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.90
Bid: 19.40
Ask: 20.40
Change: 0.00 (0.00%)
Spread: 1.00 (5.155%)
Open: 19.90
High: 19.90
Low: 19.90
Prev. Close: 19.90
KAY Live PriceLast checked at -
Kings Arms Yard VCT is an Investment Trust

To produce a regular and predictable dividend stream with an appreciation in capital value, invests in a broad portfolio of higher growth businesses across a variety of sectors of the UK economy including higher risk technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-yearly Report

29 Aug 2008 07:00

SPARK VCT PLC

HALF YEARLY FINANCIAL REPORT 2008

Financial highlightsPer ordinary share (pence) 30.06.08 31.12.07 31.08.07 Net asset value 28.7 33.2 34.2 Dividends Dividend (1) 2.8 4.2 2.8 Cumulative dividend (2) 53.7 50.9 49.5 Total return (3) SPARK VCT plc (previously called Quester VCT plc) 82.4 84.1 83.7 Return including tax benefits (5) 102.4 104.1 103.7 Total return to former shareholders of: Quester VCT 2 plc (4) 67.7 69.4 68.9 Return including tax benefits (5) 87.7 89.4 88.9 Quester VCT 3 plc (4) 42.6 44.3 44.0 Return including tax benefits (5) 62.6 64.3 64.0

1. Dividend paid or declared in the financial period ended on the date stated

2. Cumulative dividends paid by SPARK VCT plc

3. Net asset value plus cumulative dividend per share to ordinary shareholders

since the launch of Quester VCT plc, now renamed SPARK VCT plc.

4. Total return to original shareholders in Quester VCT 2 plc and Quester VCT

3 plc, which were merged with Quester VCT plc, now renamed SPARK VCT plc,

in June 2005

5. Return after 20% income tax relief but excluding capital gains deferral

Dividend

A final dividend of 2.8p per share equivalent to ‚£3,140,000 was declared at the Annual General Meeting on 18 June 2008 and is payable on 15 October 2008.

The interim management report comprises the Chairman's Statement, the Investment Manager's report, Fund Summary and note 10 to the condensed financial statements.

Chairman's statementNet assetsThe movement in net assets and net assets per share is summarised in the tablebelow: ‚£'000 Pence per Share Net asset value at 31 December 2007 37,676 33.2 Income 458 0.4 Operating expenses (664) (0.6) Movement on venture capital investments Unquoted investments 252 0.2 Quoted venture capital investments (209) (0.2) Bonds and equity investments Net loss on disposal and revaluation (779) (0.7)

Net assets before dividend, performance 36,734 32.3 incentive fee and share buy-backs

Dividend payable (3,140) (2.8)

Investment management performance incentive (1,040) (0.9) fee

Share buy-backs (328) 0.1 Net asset value at 30 June 2008 32,226 28.7 The return on the Fund's investments dropped by 0.9p per share over the sixmonths. The good progress made by a number of the portfolio companies has beenoffset by the general change in market sentiment, which has held back theoverall performance of the Fund. A few companies are cash positive, growingsatisfactorily and, given the right market conditions, nearing readiness for anexit. On balance, the earlier stage companies are gaining traction. However,the change in market sentiment resulted in the withdrawal of a buyer of onecompany very late in the day and the climate for follow-on financings hasbecome more difficult. Your Board cannot identify at this stage an investmentwhose performance might transform the overall portfolio, though a number ofcompanies may show satisfactory returns.

The environment for disposals and funding shows no sign of improving in the short term.

A fall of ‚£779,000 was suffered in the portfolio of bonds and listed equities. Given emerging cash requirements over the next two years the listed equity portfolio was sold in July for a further loss of ‚£291,000.

The main movements in net asset value were driven by the final dividend of 2.8pper share, approved at the Annual General Meeting. This triggered the paymentof the performance incentive fee, and the dividend will be payable on 15October 2008.This timing will mean that VAT will not be payable on theincentive fee: more generally, after

1 October 2008 VAT will not be payable on the management fees and will result in an ongoing annual benefit at present valuations of around ‚£100,000 per annum. Shareholders approved the new incentive scheme at the Extraordinary General Meeting on 1 July 2008.

The Board has not declared an interim dividend. As forewarned in the lastAnnual Accounts, shareholders should expect much lower dividends in the future,as cash will be retained for reinvestment in the venture capital portfolio.Dividends will depend on the rate of reinvestment and the overall performanceof the portfolio, and will be based to a greater degree than before on netincome and gains on disposal of investments.As announced at the time of the EGM, the Board confirms that, in circumstancesin which growth in the year-on-year total return results in a payment under themanagement performance incentive scheme, the Board would also expect to pay

adividend.Jock BirneyChairman29 August 2008

Directors' responsibility statement

The Directors confirm to the best of their knowledge that:

* the condensed set of financial statements contained within the Half-Yearly

Financial Report has been prepared in accordance with the Accounting Standards Board's Statement `Half-Yearly Financial Reports'; and * the interim management report includes a fair review of the information required by Disclosure and Transparency Rule 4.2.7R of important events

that have occurred during the first six months of the financial year and

their impact on the condensed set of financial statements, and a

description of the principal risks and uncertainties for the remainder of

the financial year; and

* the condensed set of financial statements (notes 4 and 10) includes a fair

review of the information concerning related parties transactions as

required by Disclosure and Transparency Rule 4.2.8R.

The Half-Yearly Financial Report was approved by the Board on 29 August 2008 and the above responsibility statement was signed on its behalf by the Chairman.

Investment manager's reportThe period covered by this interim management report has seen a change inmarket sentiment brought about by the `sub-prime' crisis. A number of keytransactions were completed prior to the change in market sentiment, notablythe sale of Nomad Payments Limited as described in the last Annual Report. Morerecently, however, the tendency towards risk aversion in the private equity andventure capital markets has made financing conditions for a number of portfoliocompanies more difficult, delayed opportunities for exits and depressed theterms on which exits may be achievable. Against this, however, for companies inthe portfolio that are addressing new markets which are growing on the back ofnew technologies or services, the general decline in market sentiment will notstop that growth. As long as they are not approaching the capital markets forfurther funding or a sale, then the value in these companies will continue todevelop well, and there are examples of companies in this category within theportfolio.Realisation of investments

Details of the successful exit from Nomad Payments Limited by trade sale toMetavante Technologies, Inc. , which closed on 10 January 2008, wereset out in the last Annual Report. This transaction realised ‚£7,263,000 (ofwhich ‚£5,588,000 has been received in cash and ‚£1,375,000 is held in escrow),for a multiple of 2.0 times original cost.

New investments

In the first six months of the year, the Company has closed one new investment,with ‚£1.0 million being committed to Isango! Limited, a growth stage companyoperating an online travel website offering users an authoritative source oftravel experiences such as holiday tours, sightseeing, attractions andactivities in more than 50 countries across the world. Isango! has seen monthlyrevenues grow by 25% on average month-on-month since the investment was made.

Progress of investments

During the six months to 30 June 2008 both the early stage companies and the more developed companies within the venture capital portfolio have shown generally satisfactory business progress.

A total of ‚£1.4 million was committed to follow-on investments during the halfyear. Among the Company's early stage investments in the TMT sector, SecernoLimited, which specialises in the supply of software and appliances to protectagainst internal and external threats to databases, was successful inconcluding a US$16 million financing led by Amadeus Capital Partners withparticipation by the SPARK-managed funds including ‚£532,000 from the Company.Also in the TMT sector, an additional ‚£372,000 was advanced as loan finance toCluster Seven Limited, the specialist provider of spreadsheet managementsoftware, ‚£129,000 to Level Four Software Limited, the specialist provider ofATM software solutions, and ‚£69,000 to Arithmatica Limited which is focused onsilicon math solutions for designers of integrated circuits. In thehealthcare sector, a follow-on investment of ‚£255,000 was made in HaemostatixLimited, the early stage company focused on platelet replacement therapies:this followed good early scientific results and a decision to accelerate therate of development of the company.Antenova Limited has demonstrated satisfactory progress in winning moreprofitable business but in consequence will require additional working capital:in present conditions, the terms of the new funding round will inevitably be lessattractive than would have been expected earlier. However, by participating inthis round at a level more than pro-rata to its previous holding, the Fund willbe taking advantage of these terms to enhance its position in the investment.UniServity Limited, which markets a web-based collaborative learningenvironment for schools, is achieving considerable success in winning contractswith Local Education Authorities in the UK and is beginning to make progressalso in international markets.Among the more developed companies in the portfolio, marketing communicationssoftware company Elateral Holdings Limited has shown encouraging tradingresults allowing for an increase in the valuation of the Fund's investment.However, Elateral was a victim of the sentiment change in markets when an offer for the acqisition of the company at substantially above this level was withdrawn by a private equity buyer on account of market turmoil.In the healthcare sector, the merger of Celldex Therapeutics, Inc. with theNASDAQ- listed AVANT Immunotherapeutics, Inc., which closed in March 2008, hasbeen well received in the market and the share price has performed well. Theshare price of MediGene AG also improved over the half year and the opportunitywas taken to sell one-third of this holding.The healthcare sector also produced some disappointments over the half year:the scientific progress of Lectus Therapeutics Limited has not lived up toexpectations and both Genosis plc and Phoqus Pharmaceuticals plc failed in theimplementation of their business plans: all three investments must now beconsidered as write-offs.Valuation changesVenture capital portfolioIn the venture capital portfolio, the sale of shares in MediGene AG generatedproceeds of ‚£140,000 and contributed to an overall ‚£32,000 gain on disposal.Revaluation of unquoted investments produced a net surplus of ‚£209,000,including ‚£774,000 in respect of a revaluation of Elateral Holdings Limitedoffset by a write-down of ‚£442,000 in respect of Antenova Limited and otheradjustments.Valuation changes in the quoted venture capital portfolio produced a surplus of‚£29,000 over the figures at 31 December 2007, including increases in the valuesof the holdings in AVANT Immunotherapeutics, Inc. and MediGene AG offset bydisappointing performances of Allergy Therapeutics plc and Oxonica plc.However, amounts totalling ‚£637,000 have been written off as an impairment ofvalue, including ‚£214,000 in respect of the residual carrying value of theinvestment in Lectus Therapeutics Limited, ‚£67,000 in respect of Genosis plcand ‚£203,000 in respect of Phoqus Pharmaceuticals.

Listed equity and bond portfolio

Approximately ‚£1.0 million was withdrawn from the bond portfolio during the sixmonths to 30 June 2008 to fund the operations of the Company. The valuation ofthe listed equity and bond portfolio fell by ‚£685,000 over the half year.

In mid July the entire portfolio of listed equities was sold (at a loss of ‚£291,000

compared with the valuation at 30 June 2008) in order to protect against the possibility of further declines in stock markets and ensure the availability ofliquidity to fund necessary follow-on investments and the operations of theCompany.

Outlook

Following the change in market sentiment, the pace of new investment is beingconstrained, pending better visibility on the timing of planned exits and theconsequent availability of resources. The management team continues to adopt astringent approach designed to ensure that the Company's follow on investmentresources are most effectively applied.It remains an objective to refresh the portfolio as soon as possible to takeadvantage of new investment opportunities available to SPARK, for example inthe digital media and software applications sectors and in medical devices anddiagnostics. Continued attention will be given to the possibility of earlyexits from under-performing investments in order to make this possible,although present market conditions make the achievement of this objective moredifficult.

SPARK Venture Management Limited Manager

29 August 2008

Fund summary as at 30 June 2008

Industry Cost Valuation Equity % of sector (1) % held fund by ‚£'000 value ‚£'000

Fifteen largest venture capital

investments Sift Group Limited TMT 2,395 2,249 20.2% 7.0% Imagesound plc TMT 2,848 1,920 11.8% 6.0% Elateral Holdings Limited TMT 1,009 1,783 24.3% 5.5% Vivacta Limited Healthcare 1,067 1,336 8.5% 4.1% Cluster Seven Limited TMT 1,569 1,197 9.0% 3.7% Skinkers Limited TMT 1,000 1,000 5.6% 3.1% UniServity Limited TMT 1,000 1,000 16.5% 3.1% Isango! Limited TMT 1,000 1,000 2.3% 3.1% Secerno Limited TMT 978 978 4.6% 3.0% Level Four Software Limited TMT 855 855 5.1% 2.7% Teraview Limited Healthcare 1,172 827 5.4% 2.6% Perpetuum Limited TMT 686 780 7.0% 2.4% Workshare Limited TMT 695 695 1.9% 2.2%

International Diagnostics Group Other 690 690 23.9% 2.1%

Limited We7 Limited TMT 674 674 10.0% 2.1% 17,638 16,984 52.7% Other venture capital investments Haemostatix Limited Healthcare 502 502 10.6% 1.6% Community Internet Europe TMT 327 365 40.0% 1.1% Limited Arithmatica Limited TMT 563 337 12.5% 1.0% Antenova Limited TMT 1,134 322 4.7% 1.0% MediGene AG FRANKFURT Healthcare 411 314 0.2% 1.0% Allergy Therapeutics plc AIM Healthcare 772 239 1.1% 0.7% Oxonica plc AIM Healthcare 204 204 1.5% 0.6% HTC Healthcare Group Limited Other 189 189 36.7% 0.6%

AVANT Immunotherapeutics, Inc. Healthcare 625 182 0.2% 0.6%

NASDAQ

Artisan Software Tools Limited TMT 120 120 23.4% 0.4%

Landround plc AIM TMT 178 115 6.3% 0.4% Casella Group Limited Other 110 110 17.8% 0.3% Symetrica Limited TMT 108 108 2.4% 0.3% Other investments:

valuations less than ‚£100,000 204 192 0.6%

(2) 5,447 3,299 10.2% Total venture capital 23,085 20,283 62.9% investments Total quoted venture capital 2,281 1,128 3.5% investments

Total unquoted venture capital 20,804 19,155 59.4%

investments 23,085 20,283 62.9% Listed fixed interest 3,848 3,828 11.9% investments Listed equity investments 5,403 5,294 16.4% Total investments 32,336 29,405 91.2% Cash and other net assets 2,821 2,821 8.8% Net assets 35,157 32,226 100.0%

1. Amounts shown as cost represent the valuation attributed to the investment

at the date of the merger in 2005 or subsequent acquisition cost as reduced

in certain cases (2) by amounts written off as representing an impairment

in value

2. Cost reduced by amounts written off as representing an impairment in value

Condensed financial statements

Profit and loss account Notes Six months Six months Ten months to to to 30.06.08 31.08.07 31.12.07 (unaudited) (unaudited) (audited) ‚£'000 ‚£'000 ‚£'000 Loss on investments at fair value through 3 (736) (4,936) (4,314)profit or loss Income 458 418 636 Investment management fee: annual fee (448) (442) (776) performance incentive fee 4 (1,040) - - Other expenses (216) (329) (432) Loss on ordinary activities before (1,982) (5,289) (4,886)taxation

Tax on loss on ordinary activities - -

-

Loss on ordinary activities after (1,982) (5,289) (4,886)taxation

Basic and fully diluted loss per share 5 (1 .8)p (4.6)p (4.3)p

All items in the above statement derive from continuing operations.

The Company has only one class of business and derives its income from investments made in shares and securities and from bank deposits.

There are no gains and losses for the period other than those passing through the profit and loss account of the Company.

The accompanying notes are an integral part of this statement.

Balance sheet Notes 30 June 31 31 August 2008 December 2007 (unaudited) 2007 (unaudited) ‚£'000 (audited) ‚£'000 ‚£'000 Fixed assets Investments at fair value through 6 29,405 36,294 37,746profit or loss Current assets Debtors 1,535 177 284 Cash at bank 5,767 1,417 1,319 7,302 1,594 1,603 Creditors: amounts falling due 7 (4,481) (212) (219)within one year Net current assets 2,821 1,382 1,384 Net assets 32,226 37,676 39,130 Capital and reserves Called-up equity share capital 5,608 5,673 5,716 Share premium account 150 150 150 Capital redemption reserve 676 611 568 Special reserve 25,272 27,615 37,478 Revaluation reserve (2,931) 945 (6,517) Profit and loss account 3,451 2,682 1,735 Total equity shareholders' funds 32,226 37,676 39,130 Net asset value per share 8 28.7p 33.2p 34.2p

The accompanying notes are an integral part of this statement.

Summarised cash flow statement

Note Six months Ten months Six months to to to 30.06.08 31.12.07 31.08.07 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000 Cash (outflow)/inflow from operating 9 (104) 125 243activities Financial investment

Purchase of venture capital investments (2,429) (3,764) (1,337)

Purchase of listed equities and fixed (1,490) (7,514) (2,898)interest investments Sale of venture capital investments 6,038 1,237

1,237

Sale/redemption of listed equity and 2,253 11,926 2,969fixed interest investments

Amounts recovered from investments 410 159

-previously written off

Total net financial investment 4,782 2,044

(29) Equity dividends paid - (4,911) (3,186) Financing Buy-back of ordinary shares, net of (328) (855)

(723)

shares issued under the dividend

reinvestment scheme Increase/(decrease) in cash for the 4,350 (3,597) (3,695)period

Reconciliation of net cash flow to

movement in net funds Increase/(decrease) in cash for the 4,350 (3,597) (3,695)period Net funds at the start of the period 1,417 5,014

5,014

Net funds at the end of the period 5,767 1,417

1,319

The accompanying notes are an integral part of this statement. Net funds comprise cash at bank and on short term deposit.

Reconciliation of movements in shareholders' funds

Share Share Capital Special Revaluation Profit Total capital premium redemption reserve reserve and loss account ‚£'000 ‚£'000 ‚£'000 ‚£'000 ‚£'000 ‚£'000 ‚£'000

At 1 January 2008 5,673 150 611 27,615 945

2,682 37,676

Shares purchased for (65) - 65 (328) -

- (328)cancellation Realisation of prior - - - - (3,429) 3,429 -years' net gains on investments Transfer from special - - - (2,015) - 2,015 -reserve to profit and loss account Net loss on - - - - (447) 447 -revaluation of investments Loss on ordinary - - - - - (1,982) (1,982)activities after taxation Dividend payable - - - - - (3,140) (3,140)

At 30 June 2008 5,608 150 676 25,272 (2,931)

3,451 32,226

The accompanying notes are an integral part of this statement.

Notes

1. The financial information contained in this Half-Yearly Financial Report

has been prepared on the basis of the accounting policies set out in the

Annual Report for the 10 months ended 31 December 2007.

The annual financial statements of the Company are prepared under the historical cost convention, except for the measurement at fair value of fixed asset investments, and in accordance with applicable UK accounting standards.

2. A final dividend in respect of the period ended 31 December 2007 of 2.8p

per share totalling ‚£3,140,000 was declared at the Annual General Meeting

on 18 June 2008 and is payable on 15 October 2008.

3. The overall loss on investments at fair value through profit or loss

disclosed in the profit and loss account is analysed as follows: Six months to Ten months to Six months to 31.08.07 31.12.07 30.06.08 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000

Net (loss)/gain on disposal (62) 460

169 Write-off of investments (637) - (5,076)

Recoveries made in respect of 410 -

159

investments previously written off Net (loss)/gain on revaluation of (447) (5,396)

434investments (736) (4,936) (4,314) Unquoted venture capital investments 252 (3,548)

(1,416)

Quoted venture capital investments (209) (1,282) (2,393) Bonds and equity investments (779) (106) (505) (736) (4,936) (4,314)

`Net gain on disposal' represents the difference between proceeds received and the carrying values of those investments sold during the period.

The amounts reported under `write-off of investments' represent the proportionof the carrying value that have, in the opinion of the Directors, suffered animpairment in value.

4. Under the amended and restated agreement dated 20 May 2005 with SPARK

Venture Management Limited, formerly called Quester Capital Management Limited (the Manager), upon the Company having paid or declared by 31 December 2008 cash dividends (excluding 1.0p of the special interim dividend paid post the merger of the Company with Quester VCT 2 plc and

Quester VCT 3 plc in June 2005) of an aggregate amount equal to 20% or more

of the Company's Formula Asset Value at the date of the merger (FAV), the

Manager is entitled to a performance incentive fee of 2% of the FAV (‚£1

,040,000) . Following the declaration at the Annual General Meeting of a

final dividend of 2.8p per share in respect of the period ended 31 December

2007, the total of cash dividends (excluding 1.0p of the special interim

dividend) paid or declared over this period amounts to 11.15p per share or

25% of the FAV. The performance inventive fee will be payable following

payment of the final dividend on 15 October 2008.

5. The loss per share of 1 .8p (six months ended 31 August 2007: loss 4.6p) is

based on the loss on ordinary activities after tax of ‚£1,982,000 (six

months ended 31 August 2007: loss ‚£5,289,000) and on the weighted average

number of ordinary shares in issue during the period of 112,759,987 (six

months ended 31 August 2007: 115,321,504).

The loss per share of 4.3p for the ten months ended 31 December 2007 is basedon the loss on ordinary activities after tax of ‚£4,886,000 and on the weightedaverage number of ordinary shares in issue during the period of 114,784,742. 6. Movements in investments during the six months ended 30 June 2008 are as follows: Venture Bonds & Total capital equity investments investments ‚£'000 ‚£'000 ‚£'000 Cost at 1 January 2008 25,098 10,252 35,350 Net gain at 1 January 2008 536 408 944 Valuation at 1 January 2008 25,634 10,660 36,294 Movements in the period: Purchases at cost 2,429 1,490 3,919 Disposals - proceeds (7,413) (2,253) (9,666)

- net gains/(losses) on disposal 32 (94)

(62) Impairment in value (637) - (637)

Amortisation of fixed interest - 4

4investments Net gain/(loss) on revaluation of 238 (685) (447)investments Valuation at 30 June 2008 20,283 9,122 29,405 Book cost at 30 June 2008 23,085 9,251 32,336 Net loss at 30 June 2008 (2,802) (129) (2,931) Valuation at 30 June 2008 20,283 9,122 29,405

Amounts shown as cost represent the valuation attributed to the investment at the date of the merger in 2005 or subsequent acquisition cost, less any reduction made on accounts of impairment in value.

Bonds and equity investments at valuation at 30 June 2008 include listed fixedinterest investments of ‚£3,828,000 (31 December 2007: ‚£4,860,000) and listedequity investments of ‚£5,294,000 (31 December 2007: ‚£5,800,000).

7. Creditors (amounts falling due within one year) are as follows:

30.06.08 31.12.07 ‚£'000 ‚£'000 Dividend payable 3,140 - Investment management fee: performance incentive fee 1,040 - Accruals 301 212 4,481 212

8. The net asset value per share as at 30 June 2008 of 28.7p (31 December

2007: 33.2p) is based on net assets of ‚£32,226,000 (31 December 2007: ‚£

37,676,000) and on the 112,157,948 ordinary shares in issue at that date

(31 December 2007: 11 3,453,270).There is no dilution effect in respect of

the period ended 30 June 2008 (year ended 31 December 2007: nil).

9. Reconciliation of operating loss to cash (outflow)/inflow from operating

activities for the period is as follows:

Six months to Ten months to Six months to 30.06.08 31.12.07 31.08.07 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000

Loss on ordinary activities before tax (1,982) (4,886) (5,289)

Loss on investments at fair value 736 4,314 4,936through profit or loss Decrease in debtors 17 812 705 Increase/(decrease) in creditors 1,129 (122)

(115)

Amortisation of fixed interest (4) 7

6investments

Cash (outflow)/inflow from operating (104) 125

243

activities 10.Spark Investors Limited (a fellow subsidiary of the Manager), of which ABCarruthers is a director, may from time to time be eligible to receivetransaction fees and/or directors' fees from investee companies. During theperiod to 30 June 2008, fees of ‚£22,000 attributable to the investments of theCompany were received pursuant to these arrangements (10 months ended 31December 2007: ‚£39,000 paid to Quester Services Limited of which APG Holmes wasa director until 11 May 2007 and AB Carruthers was a director from that date).11.This Half-Yearly Financial Report has been neither audited nor reviewed bythe Company's auditors and does not constitute statutory accounts. Thestatutory accounts for the period ended 31 December 2007 have been delivered tothe Registrar of Companies and received an audit report which was unqualified,did not include a reference to any matters to which the auditors drew attentionby way of emphasis without qualifying the report and did not contain anystatements under Section 237 (2) and (3) of the Companies Act 1985.

12.Interim management statements relating to the first and third quarters of the financial year will be released via the Regulatory News Service on or shortly before 19 May and 19 November each year.

13.Copies of the Half-Yearly Financial Report are expected to be sent to shareholders on or about 3 September 2008. Further copies can be obtained from the Company's registered office.

A copy of the above document is to be submitted to the UK Listing Authority, and will shortlybe available for inspection at the UK Listing Authority's Document Viewing

Facility, whichis situated at :Financial Services Authority25 North ColonnadeCanary WharfLondon E14 5HS

vendor
Date   Source Headline
28th Mar 20242:00 pmGNWTotal voting rights and Capital
25th Mar 20242:30 pmGNWDirector/PDMR Shareholding
25th Mar 202410:15 amGNWIssue of Equity and Total Voting Rights
19th Mar 20249:32 amGNWCLOSURE OF THE COMPANY'S OFFER
12th Mar 20243:30 pmGNWNAV announcement and Portfolio company update
29th Feb 20242:00 pmGNWTotal voting rights and Capital
31st Jan 20241:30 pmGNWTotal voting rights and Capital
29th Dec 20231:00 pmGNWTotal voting rights and Capital
19th Dec 20235:37 pmGNWTransaction in Own Shares and Total Voting Rights and Capital
15th Dec 20233:45 pmGNWPublication of Prospectus
5th Dec 202312:49 pmGNWKings Arms Yard VCT PLC: Interim Management Statement
30th Nov 20232:00 pmGNWTotal voting rights and Capital
1st Nov 20239:41 amGNWDirector/PDMR Shareholding
31st Oct 20239:48 amGNWIssue of Equity and Total Voting Rights and Capital
30th Oct 20232:00 pmGNWChange of the Company's Auditor
19th Oct 20232:54 pmGNWTransaction in Own Shares and Total Voting Rights and Capital
12th Oct 202310:30 amGNWStatement regarding the proposed issue of a prospectus
29th Sep 20232:29 pmGNWTotal voting rights and Capital
22nd Sep 202312:50 pmGNWKings Arms Yard VCT PLC: Half-yearly Financial Report
1st Sep 202311:15 amGNWDirectorate change
31st Aug 20232:00 pmGNWTotal voting rights and Capital
31st Jul 20232:14 pmGNWTotal voting rights and Capital
30th Jun 20232:10 pmGNWTotal voting rights and Capital
29th Jun 20231:50 pmGNWTransaction in Own Shares and Total Voting Rights and Capital
7th Jun 20236:52 pmGNWAGM Statement
7th Jun 202311:41 amGNWKings Arms Yard VCT PLC: Interim Management Statement
31st May 20232:00 pmGNWTotal voting rights and Capital
28th Apr 202310:23 amGNWDirector/PDMR Shareholding
28th Apr 202310:22 amGNWIssue of Equity and Total Voting Rights and Capital
19th Apr 20235:30 pmGNWTransaction in Own Shares and Total Voting Rights and Capital
19th Apr 20239:03 amGNWDirectorate Notification
14th Apr 20232:30 pmGNWIssue of Equity and Total Voting Rights and Capital
11th Apr 20234:45 pmGNWPublication of a supplementary prospectus
5th Apr 20236:04 pmGNWKings Arms Yard VCT PLC: Annual Financial Report
31st Mar 20232:30 pmGNWIssue of Equity and Total Voting Rights and Capital
29th Mar 20231:19 pmGNWDividend Declaration
16th Mar 20239:09 amGNWClosure of the Company's offer
28th Feb 20232:00 pmGNWTotal voting rights and Capital
24th Feb 20236:26 pmGNWChange of Allotment Date
23rd Feb 202312:45 pmGNWNAV Announcement
31st Jan 20232:00 pmGNWTotal voting rights and Capital
18th Jan 20233:49 pmGNWOffer Update
30th Dec 202212:00 pmGNWTotal voting rights and Capital
19th Dec 20226:06 pmGNWTransaction in Own Shares and Total Voting Rights and Capital
5th Dec 20223:45 pmGNWDirector/PDMR Shareholding
5th Dec 202212:15 pmGNWIssue of Equity and Total Voting Rights and Capital
30th Nov 20222:15 pmGNWDirectorate change
30th Nov 20222:00 pmGNWTotal voting rights and Capital
28th Nov 202211:46 amGNWKings Arms Yard VCT PLC: Interim Management Statement
14th Oct 20224:20 pmGNWTransaction in Own Shares and Total Voting Rights and Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.